|
| Genotype 1 (n = 24) | Genotype 2 (n = 60) |
| Epidemiological parameters |
|
|
| Gender |
|
|
| Male | 16 (66.67) | 42 (70) |
| Female | 8 (33.33) | 18 (30) |
| Age in years: median (IQR) | 54.29 (46.25 - 64) | 54.5 (45.75 - 61) |
| Direct-acting antivirals used |
|
|
| SFV/LDV n (%) | 15 (62.50) | 0 (0) |
| SFV/DCV n (%) | 8 (33.33) | 10 (16.67) |
| SFV/RBV n (%) | 0 (0) | 49 (81.66) |
| SFV/DCV/RBV n (%) | 1 (4.17) | 1 (1.67) |
| Virological markers |
|
|
| HCV RNA in UI/ml: median (IQR) | 813,221 (281,561 - 3,111,701) | 688,600 (233,000 - 4,792,000) |
| HCV RNA in log: median (IQR) | 5.895 (5.450 - 6.423) | 5.830 (5.265 - 6.680) |
| Hepatopathy information |
|
|
| Cirrhosis (Fibrosis F4): n (%) | 3 (12.50) | 11 (18.33) |
| Methods for assessing fibrosis |
|
|
| FIB-4: n (%) | 24 (100) | 57 (95) |
| FIB-4: median (IQR) | 2.625 (1.360 - 3.5530) | 2.370 (1.260 - 4.590) |
| APRI: n (%) | 24 (100) | 57 (95) |
| APRI: median (IQR) | 0.855 (0.4475 - 1.4125) | 0.99 (0.61 - 2.260) |
| Fibrotest: n (%) | 20 (83.33) | 50 (83.33) |
| AST (UI/l): median (IQR) | 52 (34 - 83) | 56 (40 - 104.8) |
| ALT (UI/l): median (IQR) | 66 (33.75 - 85.25) | 66.5 (40 - 104.8) |
| Biological parameters: median (IQR) |
|
|
| Platelets (/mm3) | 172.5 (131.8 - 213.5) | 168 (133 - 200) |
| Neutrophil (/mm3) | 1650 (1245 - 2612) | 1894 (1462 - 2294) |
| Haemoglobin (g/dl) | 12.7 (11.22 - 13.55) | 13.3 (12.05 - 14.80) |